Floatz logo

Sasanlimab

Head And Neck Cancer

Pfizermonoclonal_antibodyPhase 1Active
D
28/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
13/ 100
Competitive Position
73/ 100

Competitive context

141 Active assets in the Head And Neck Cancer cohort.

Asset / SponsorPhaseRating
NEPENTHE
Instituto Nacional de Cancer, Brazil
Phase 4BB
CIS-DIAMMINEDICHLOROPLATINUM II
ImmunityBio, Inc.
Phase 3BB
LIDOCAINE
Instituto Nacional de Cancer, Brazil
Phase 3BB
Carboplatin
Rapa Therapeutics LLC
Phase 3BB
Epirubicin
Thomas Jefferson University
Phase 3BB

View all 50 →

Same molecule, other indications

Sasanlimab is also rated in:

non-small cell lung carcinomaDormant
CC
Indicative ·
41 / 100
View asset →
renal cell carcinomaDormant
C
Indicative ·
39 / 100
View asset →
neoplasmDormant
C
Indicative ·
39 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →